Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

GKOSBullishIndustry Newsnews

High materiality8/10

Glaukos Phase 4 iDose TR combo shows superior IOP reduction

Oct 9, 2026, 1:59 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong efficacy gain and a favorable safety profile in Phase 4 can de-risk the program, potentially improving developer confidence, partnerships, and valuation upside despite no immediate revenue impact.

AI summary

What happened, with direct paths to the underlying reporting

Glaukos announced topline Phase 4 results for iDose TR used with cataract surgery, showing better diurnal IOP reduction than cataract surgery alone (11.1 mmHg vs 7.4 mmHg at three months; incremental 3.6 mmHg). The safety profile is favorable with no related endothelial loss or CME, supporting the therapy's potential to address patient non-compliance through extended delivery (up to 3 years).

GKOS reports Phase 4 topline for iDose TR cataract therapy.
Combined therapy lowers mean diurnal IOP more than surgery alone.
Phase 4: 149 randomized eyes; 74 combo, 75 control.
Safety: no treatment-related corneal endothelial loss or CME reported.
iDose TR provides up to three years of travoprost delivery.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Glaukos Phase 4 iDose TR combo shows superior IOP reduction

Glaukos demonstrates three-year durability for keratoconus treatment data release

These Analysts Boost Their Forecasts On Glaukos Following Q4 Results

US FDA approves Glaukos' new eye therapy

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery